TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Breastfeeding impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe infant morbidity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of core-temperature measurements exceeding 38 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of core-temperature measurements exceeding 38.5 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetic retinopathy (DR) incidence/progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Visual acuity outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: DME incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: days of paid employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: rates of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Arrival by emergency medical services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presentation to the hospital within 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgE levels to Der p 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rhinitis symptom and medication scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative lifetime breast cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: estimated blood loss during cystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prescriber implementation rates of STOPP and START recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Absolute risk reduction in patients with ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: subjective wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in the number of antianginal drugs used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate response to CRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for CRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personality/behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self Care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of withdrawal from tacrine
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge rate
Endpoint domain: Mortality/survival
Primary endpoint: isometric mid thigh pull peak force change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Confidence in using MI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interest in MI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Commitment to using MI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: wound closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean absolute healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement score of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effectiveness predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statistical power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalizability of trial results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infected canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: attenuated positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of smokers who quit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of the questionnaire of motivation for abstaining from drugs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of diabetes optimal care measures met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine amino transferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: aspartate aminotransferase (AST) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: gamma-glutamyl transferase (gammaGT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Routine use of BMI percentiles to screen for childhood obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale‐Brown Obsessive Compulsive Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control group failure probabilities
Endpoint domain: Mortality/survival
Primary endpoint: Edema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematochezia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of urine scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in FLAIR hyperintensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized intensity values on ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized intensity values on restriction spectrum imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to full enteral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pass first stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma level of total IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in plasma level of IgG1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in plasma level of IgG2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in plasma level of IgG3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in general ill feelings/nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAD depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: beneficial effects on structural and molecular skin parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Size of the Hoffmann-reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function after endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression-Free Survival (PFS) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Local Control (LC) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Postprocedural hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Renal failure
Endpoint domain: Adverse events/effects
Primary endpoint: Facial recognition impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Secondary stroke prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Classroom Climate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MI rates
Endpoint domain: Mortality/survival
Primary endpoint: Weighted cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Yale‐Brown Obsessive‐Compulsive Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0–t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response for delayed nausea and vomiting in patients with highly emetogenic chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete response for delayed nausea and vomiting in patients with moderately emetogenic chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life (QoL) evolution
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postural tremor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand weakness
Endpoint domain: Adverse events/effects
Primary endpoint: Time to termination of exercise tolerance testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to onset of angina during exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of total angina attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe anaphylactoid reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Worsening of dementia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decreased chitinase-3-like protein-1 (YKL-40) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of peri-implant diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: patient satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative metastasis rate
Endpoint domain: Mortality/survival
Primary endpoint: Death rate following melanoma metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Median reduction in plasma viral load (VL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of IAD after treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores of SCL-90 after treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OC knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean horizontal and vertical movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0, infinity) of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(1/2) of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization of the airway with new gastric organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of postoperative pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Total I-PSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to relapse of TAK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of PLT transfusions per infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects receiving PLT transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding, morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Comfort level of eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Explosive leg power improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comprehension test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trust ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blame attributions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Final success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vesical neck mobility during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h urinary albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24 h urinary protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cystatin C‐based glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients with multiple sites of progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Desaturase activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Doctor offered help to stop smoking
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Doctor offered help to stop exposing children to ETS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: exogenous carbohydrate oxidation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cost per DALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of complete sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite end point of death, myocardial infarction, or target vessel revascularization (TVR) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Need for target vessel revascularization (TVR) at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dyspnea assessed by Borg score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of cough assessed by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCD rates
Endpoint domain: Mortality/survival
Primary endpoint: VT/VF rates
Endpoint domain: Mortality/survival
Primary endpoint: composite outcome of death, MI, stroke, or stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total plasma homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abdominal adipose tissue FAAH gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new enhancing magnetic resonance imaging lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean volume of enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IL-6 response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exercise-induced oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary excretion of leukotriene E4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Corneal staining improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Eye and Visual Function symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DBP response after RE session leading to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SBP response after RE session not to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decline in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Antiradical potential of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 (Partial Pressure of Oxygen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SatO2 (Oxygen Saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decline in GCS scores postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Poor eGOS score at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: urgency urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean voided volume per micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICG-PDR for predicting non-spontaneous recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of inlays after 10 years
Endpoint domain: Mortality/survival
Primary endpoint: task-specific anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with localized EASI<2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in the number of infiltrating CD45+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: verbal working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average weight loss (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean symptom‐free days per 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Colonization of Candida albicans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stability of Ishak fibrosis staging scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvements in Ishak necroinflammatory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage inhibition of thromboxane B(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: urinary cortisol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: anterior knee VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior knee VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-home consumption of SSB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for psychiatric hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Total number of psychiatric hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total nights for psychiatric admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Colonization rate of telemetry systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: uncontrolled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal head position of child occupants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence at 6 weeks post MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month death/readmission risk
Endpoint domain: Mortality/survival
Primary endpoint: Maximum concentration (C(max)) of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve extrapolated to infinity (AUC∞) of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median first 24-hour intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ocular pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac index augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic vascular resistance decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular filling pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes